FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288032968> ?p ?o ?g. }

• W4288032968 endingPage "555" @default.
• W4288032968 startingPage "543" @default.
• W4288032968 abstract "The Heart Failure Collaboratory (HFC) has developed a score integrating classes and doses of guideline-directed medical therapies prescribed for patients with heart failure (HF) and reduced ejection fraction. One potential use of this score is to test whether new treatments demonstrate incremental benefits, even in patients receiving comprehensive guideline-directed medical therapy.The authors investigated the efficacy of dapagliflozin according to a modified HFC score in the DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) trial.In DAPA-HF, 4,744 patients with HF and reduced ejection fraction were randomized to dapagliflozin or placebo. The modified HFC score accounted for race and electrocardiogram rhythm and rate, with a maximum possible score of 100%. The primary outcome was the composite of worsening HF or cardiovascular death.The median modified HFC score was 50% (IQR: 27.5%-62.5%; range 0%-100%). Compared with the lowest tertile, the highest tertile of the treatment score was associated with a lower risk of worsening HF or cardiovascular death (tertile 1, reference; tertile 2, HR: 0.97 [95% CI: 0.82-1.14]; tertile 3, HR: 0.83 [95% CI: 0.70-0.99]). Dapagliflozin reduced the risk of worsening HF or cardiovascular death, irrespective of treatment score (the HRs for dapagliflozin vs placebo from tertile 1 to 3 were: 0.76 [95% CI: 0.61-0.94], 0.76 [95% CI: 0.60-0.97], and 0.71 [95% CI: 0.55-0.90]), respectively; Pinteraction = 0.89). Consistent benefits were observed for HF hospitalization, cardiovascular death, all-cause mortality, and improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TTS).Dapagliflozin, compared with placebo, improved all outcomes examined, regardless of the modified HFC score. This score can be easily calculated in clinical trials and used to evaluate the incremental effects of new treatments. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124)." @default.
• W4288032968 created "2022-07-27" @default.
• W4288032968 creator A5007964446 @default.
• W4288032968 creator A5012551917 @default.
• W4288032968 creator A5018432247 @default.
• W4288032968 creator A5018872642 @default.
• W4288032968 creator A5024144703 @default.
• W4288032968 creator A5027213857 @default.
• W4288032968 creator A5030057930 @default.
• W4288032968 creator A5030399648 @default.
• W4288032968 creator A5034537174 @default.
• W4288032968 creator A5035803645 @default.
• W4288032968 creator A5049320403 @default.
• W4288032968 creator A5052533254 @default.
• W4288032968 creator A5054830306 @default.
• W4288032968 creator A5058444528 @default.
• W4288032968 creator A5061881316 @default.
• W4288032968 creator A5079993448 @default.
• W4288032968 creator A5080652506 @default.
• W4288032968 creator A5082017828 @default.
• W4288032968 date "2022-08-01" @default.
• W4288032968 modified "2023-10-09" @default.
• W4288032968 title "Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score" @default.
• W4288032968 cites W2012053212 @default.
• W4288032968 cites W2070844603 @default.
• W4288032968 cites W2081730623 @default.
• W4288032968 cites W2105138814 @default.
• W4288032968 cites W2129711762 @default.
• W4288032968 cites W2592176942 @default.
• W4288032968 cites W2883756867 @default.
• W4288032968 cites W2923389432 @default.
• W4288032968 cites W2926726860 @default.
• W4288032968 cites W2957825956 @default.
• W4288032968 cites W2974260792 @default.
• W4288032968 cites W2984683166 @default.
• W4288032968 cites W3013689722 @default.
• W4288032968 cites W3162874585 @default.
• W4288032968 cites W3193598686 @default.
• W4288032968 cites W4210374586 @default.
• W4288032968 doi "https://doi.org/10.1016/j.jchf.2022.03.009" @default.
• W4288032968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35902157" @default.
• W4288032968 hasPublicationYear "2022" @default.
• W4288032968 type Work @default.
• W4288032968 citedByCount "5" @default.
• W4288032968 countsByYear W42880329682022 @default.
• W4288032968 countsByYear W42880329682023 @default.
• W4288032968 crossrefType "journal-article" @default.
• W4288032968 hasAuthorship W4288032968A5007964446 @default.
• W4288032968 hasAuthorship W4288032968A5012551917 @default.
• W4288032968 hasAuthorship W4288032968A5018432247 @default.
• W4288032968 hasAuthorship W4288032968A5018872642 @default.
• W4288032968 hasAuthorship W4288032968A5024144703 @default.
• W4288032968 hasAuthorship W4288032968A5027213857 @default.
• W4288032968 hasAuthorship W4288032968A5030057930 @default.
• W4288032968 hasAuthorship W4288032968A5030399648 @default.
• W4288032968 hasAuthorship W4288032968A5034537174 @default.
• W4288032968 hasAuthorship W4288032968A5035803645 @default.
• W4288032968 hasAuthorship W4288032968A5049320403 @default.
• W4288032968 hasAuthorship W4288032968A5052533254 @default.
• W4288032968 hasAuthorship W4288032968A5054830306 @default.
• W4288032968 hasAuthorship W4288032968A5058444528 @default.
• W4288032968 hasAuthorship W4288032968A5061881316 @default.
• W4288032968 hasAuthorship W4288032968A5079993448 @default.
• W4288032968 hasAuthorship W4288032968A5080652506 @default.
• W4288032968 hasAuthorship W4288032968A5082017828 @default.
• W4288032968 hasBestOaLocation W42880329681 @default.
• W4288032968 hasConcept C126322002 @default.
• W4288032968 hasConcept C134018914 @default.
• W4288032968 hasConcept C142724271 @default.
• W4288032968 hasConcept C164705383 @default.
• W4288032968 hasConcept C168563851 @default.
• W4288032968 hasConcept C197934379 @default.
• W4288032968 hasConcept C204787440 @default.
• W4288032968 hasConcept C27081682 @default.
• W4288032968 hasConcept C2777180221 @default.
• W4288032968 hasConcept C2777422806 @default.
• W4288032968 hasConcept C2778198053 @default.
• W4288032968 hasConcept C555293320 @default.
• W4288032968 hasConcept C71924100 @default.
• W4288032968 hasConcept C78085059 @default.
• W4288032968 hasConceptScore W4288032968C126322002 @default.
• W4288032968 hasConceptScore W4288032968C134018914 @default.
• W4288032968 hasConceptScore W4288032968C142724271 @default.
• W4288032968 hasConceptScore W4288032968C164705383 @default.
• W4288032968 hasConceptScore W4288032968C168563851 @default.
• W4288032968 hasConceptScore W4288032968C197934379 @default.
• W4288032968 hasConceptScore W4288032968C204787440 @default.
• W4288032968 hasConceptScore W4288032968C27081682 @default.
• W4288032968 hasConceptScore W4288032968C2777180221 @default.
• W4288032968 hasConceptScore W4288032968C2777422806 @default.
• W4288032968 hasConceptScore W4288032968C2778198053 @default.
• W4288032968 hasConceptScore W4288032968C555293320 @default.
• W4288032968 hasConceptScore W4288032968C71924100 @default.
• W4288032968 hasConceptScore W4288032968C78085059 @default.
• W4288032968 hasIssue "8" @default.
• W4288032968 hasLocation W42880329681 @default.
• W4288032968 hasLocation W42880329682 @default.
• W4288032968 hasLocation W42880329683 @default.

• next